- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05976763
Test del trattamento continuo rispetto a quello intermittente con il farmaco in studio Zanubrutinib per i pazienti anziani con linfoma a cellule del mantello precedentemente non trattato
Uno studio randomizzato di fase 3 di terapia di mantenimento continua o intermittente con zanubrutinib come trattamento iniziale nei pazienti anziani con linfoma mantellare
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
- Procedura: Biospecimen Collection
- Biologico: Rituximab
- Procedura: Computed Tomography
- Procedura: Magnetic Resonance Imaging
- Altro: Questionnaire Administration
- Procedura: Positron Emission Tomography
- Procedura: Colonoscopy
- Altro: Patient Observation
- Procedura: Esophagogastroduodenoscopy
- Droga: Zanubrutinib
- Procedura: Bone Marrow Biopsy
- Altro: Fludeoxyglucose F-18
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. To compare time to first progression or death (progression free survival [PFS]1) with continuous treatment (Arm A) and time to second progression or death (PFS2) with intermittent treatment that is restarted at first progression (Arm B).
KEY SECONDARY OBJECTIVE:
I. To compare overall survival between patients who achieve a complete remission (CR) with induction therapy subsequently treated with continuous treatment versus (vs.) intermittent treatment as part of maintenance therapy.
SECONDARY OBJECTIVES:
I. To determine overall response rate (ORR) and CR rate to induction therapy with zanubrutinib and rituximab in previously untreated MCL.
II. To determine adverse events during induction and post-induction in each study arm (Arm A and B) by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.
III. To determine PFS1, event free survival (EFS) and overall survival (OS) in each study arm (A and B).
IV. To determine the overall response rate (ORR) and complete response rate (CR) after restarting zanubrutinib, following the first progression, in the intermittent treatment arm (Arm B).
V. To compare burden of symptomatic adverse events (AEs) as assessed by Patient-Reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) between patients randomized to Arm A versus Arm B.
QUALITY OF LIFE PRIMARY OBJECTIVE:
I. To compare health-related quality of life (QOL) at 12 months post-randomization as assessed by the Functional Assessment of Cancer Therapy (FACT) Lymphoma Symptom Index-18 (FLYMSI-18) total score between patients randomized to Arm A versus Arm B.
QUALITY OF LIFE SECONDARY OBJECTIVES:
I. To compare health-related QOL at other time points as assessed by the FLYMSI-18 total score between patients randomized to Arm A versus Arm B.
II. To compare burden of symptomatic AEs as assessed by PRO-CTCAE between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment.
QUALITY OF LIFE EXPLORATORY OBJECTIVES:
I. To compare the geriatric functional and cognitive PRO as assessed by Elderly Functional Index (ELFI) and Neurology (Neuro) QOL in Arm A versus Arm B.
II. To compare cognitive function at various time points as assessed by the Neuro-QOL between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment.
EXPLORATORY OBJECTIVES:
I. To evaluate the completion rate of a lymphoma-specific patient assessment of life survey (PALS) with patient directed questions on life, health, and social determinants of health (SDH) and assess the impact of the survey collected data on outcomes for all enrolled patients (study arms A and B).
II. To evaluate minimal residual disease (MRD) in those patients who achieve a CR after induction therapy (arms A and B) and how detectable MRD status changes after continued therapy vs. discontinuation of therapy (i.e. arms A vs. B).
OUTLINE:
INDUCTION THERAPY: Patients receive zanubrutinib orally (PO) twice daily (BID) on days 1-28 of each cycle and rituximab intravenously (IV) on day 1 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. . Patients undergo bone marrow biopsy and fluciclovine F18 (FDG) positron emission tomography (PET)/ computed tomography (CT) or CT throughout the trial. Patients may also undergo esophagogastroduodenoscopy (EGD) and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.
MAINTENANCE THERAPY: Patients achieving a CR after induction therapy are randomized to 1 of 2 arms.
ARM A: Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days until first disease progression on study. Patients undergo CT or magnetic resonance imaging (MRI) or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.
ARM B: Patients undergo observation until first disease progression and then receive zanubrutinib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial and may undergo bone marrow biopsy on study.
After completion of study treatment, patients are followed within 30 days and every 6 months for 10 years.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Destin Carlisle
- Numero di telefono: 773-702-8824
- Email: dcarlisle@bsd.uchicago.edu
Backup dei contatti dello studio
- Nome: Anne Beaven, MD
- Numero di telefono: 919-966-9268
- Email: anne_beaven@med.unc.edu
Luoghi di studio
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- Reclutamento
- University of Arkansas for Medical Sciences
-
Contatto:
- Site Public Contact
- Numero di telefono: 501-686-8274
-
Investigatore principale:
- Cesar Gentille
-
-
California
-
Beverly Hills, California, Stati Uniti, 90211
- Reclutamento
- Tower Cancer Research Foundation
-
Investigatore principale:
- Justin M. Darrah
-
Contatto:
- Site Public Contact
- Email: towercancerresearch@toweroncology.com
-
Duarte, California, Stati Uniti, 91010
- Attivo, non reclutante
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Stati Uniti, 92618
- Attivo, non reclutante
- City of Hope at Irvine Lennar
-
Los Angeles, California, Stati Uniti, 90048
- Reclutamento
- Cedars-Sinai Medical Center
-
Investigatore principale:
- Justin M. Darrah
-
Contatto:
- Site Public Contact
- Numero di telefono: 310-423-2133
- Email: Cancer.trial.info@cshs.org
-
-
Connecticut
-
Derby, Connecticut, Stati Uniti, 06418
- Reclutamento
- Smilow Cancer Hospital-Derby Care Center
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Fairfield, Connecticut, Stati Uniti, 06824
- Reclutamento
- Smilow Cancer Hospital Care Center-Fairfield
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Glastonbury, Connecticut, Stati Uniti, 06033
- Reclutamento
- Smilow Cancer Hospital Care Center at Glastonbury
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Greenwich, Connecticut, Stati Uniti, 06830
- Reclutamento
- Smilow Cancer Hospital Care Center at Greenwich
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Guilford, Connecticut, Stati Uniti, 06437
- Reclutamento
- Smilow Cancer Hospital Care Center - Guilford
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Hartford, Connecticut, Stati Uniti, 06105
- Reclutamento
- Smilow Cancer Hospital Care Center at Saint Francis
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
New Haven, Connecticut, Stati Uniti, 06520
- Reclutamento
- Yale University
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
North Haven, Connecticut, Stati Uniti, 06473
- Reclutamento
- Yale-New Haven Hospital North Haven Medical Center
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Stamford, Connecticut, Stati Uniti, 06902
- Reclutamento
- Smilow Cancer Hospital Care Center at Long Ridge
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Torrington, Connecticut, Stati Uniti, 06790
- Reclutamento
- Smilow Cancer Hospital-Torrington Care Center
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Trumbull, Connecticut, Stati Uniti, 06611
- Reclutamento
- Smilow Cancer Hospital Care Center-Trumbull
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Waterbury, Connecticut, Stati Uniti, 06708
- Reclutamento
- Smilow Cancer Hospital-Waterbury Care Center
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
Waterford, Connecticut, Stati Uniti, 06385
- Reclutamento
- Smilow Cancer Hospital Care Center - Waterford
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
-
Delaware
-
Newark, Delaware, Stati Uniti, 19713
- Reclutamento
- Helen F Graham Cancer Center
-
Investigatore principale:
- Gregory A. Masters
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-623-4450
- Email: lbarone@christianacare.org
-
Newark, Delaware, Stati Uniti, 19713
- Reclutamento
- Medical Oncology Hematology Consultants PA
-
Investigatore principale:
- Gregory A. Masters
-
Contatto:
- Site Public Contact
- Numero di telefono: 302-623-4450
- Email: lbarone@christianacare.org
-
-
Georgia
-
Albany, Georgia, Stati Uniti, 31701
- Reclutamento
- Phoebe Putney Memorial Hospital
-
Investigatore principale:
- Locke J. Bryan
-
Contatto:
- Site Public Contact
- Numero di telefono: 229-312-0405
- Email: ga_cares@augusta.edu
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University Hospital/Winship Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-778-1868
-
Investigatore principale:
- Jonathon B. Cohen
-
Atlanta, Georgia, Stati Uniti, 30303
- Reclutamento
- Grady Health System
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-778-1868
-
Investigatore principale:
- Jonathon B. Cohen
-
Atlanta, Georgia, Stati Uniti, 30308
- Reclutamento
- Emory University Hospital Midtown
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-946-7447
-
Investigatore principale:
- Jonathon B. Cohen
-
Atlanta, Georgia, Stati Uniti, 30342
- Reclutamento
- Emory Saint Joseph's Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-851-7115
-
Investigatore principale:
- Jonathon B. Cohen
-
Augusta, Georgia, Stati Uniti, 30912
- Reclutamento
- Augusta University Medical Center
-
Investigatore principale:
- Locke J. Bryan
-
Contatto:
- Site Public Contact
- Numero di telefono: 706-721-2388
- Email: ga_cares@augusta.edu
-
Johns Creek, Georgia, Stati Uniti, 30097
- Reclutamento
- Emory Johns Creek Hospital
-
Investigatore principale:
- Jonathon B. Cohen
-
Contatto:
- Site Public Contact
- Numero di telefono: 404-778-5714
- Email: m.lisa.hwang@emory.edu
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83712
- Reclutamento
- Saint Luke's Cancer Institute - Boise
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
Boise, Idaho, Stati Uniti, 83706
- Reclutamento
- Saint Alphonsus Cancer Care Center-Boise
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-3671
- Email: stephanie.couch@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Caldwell, Idaho, Stati Uniti, 83605
- Reclutamento
- Saint Alphonsus Cancer Care Center-Caldwell
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-3671
- Email: stephanie.couch@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Coeur d'Alene, Idaho, Stati Uniti, 83814
- Reclutamento
- Kootenai Health - Coeur d'Alene
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Fruitland, Idaho, Stati Uniti, 83619
- Reclutamento
- Saint Luke's Cancer Institute - Fruitland
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
Meridian, Idaho, Stati Uniti, 83642
- Reclutamento
- Saint Luke's Cancer Institute - Meridian
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
Nampa, Idaho, Stati Uniti, 83687
- Reclutamento
- Saint Luke's Cancer Institute - Nampa
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 208-381-2774
- Email: eslinget@slhs.org
-
Nampa, Idaho, Stati Uniti, 83687
- Reclutamento
- Saint Alphonsus Cancer Care Center-Nampa
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Post Falls, Idaho, Stati Uniti, 83854
- Reclutamento
- Kootenai Clinic Cancer Services - Post Falls
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Stati Uniti, 83864
- Reclutamento
- Kootenai Clinic Cancer Services - Sandpoint
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
-
Illinois
-
Bloomington, Illinois, Stati Uniti, 61704
- Reclutamento
- Illinois CancerCare-Bloomington
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Canton, Illinois, Stati Uniti, 61520
- Reclutamento
- Illinois CancerCare-Canton
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Carthage, Illinois, Stati Uniti, 62321
- Reclutamento
- Illinois CancerCare-Carthage
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Chicago, Illinois, Stati Uniti, 60612
- Reclutamento
- University of Illinois
-
Contatto:
- Site Public Contact
- Numero di telefono: 312-355-3046
-
Investigatore principale:
- Carlos Galvez
-
Chicago, Illinois, Stati Uniti, 60606
- Reclutamento
- Alliance for Clinical Trials in Oncology
-
Investigatore principale:
- Anne W. Beaven
-
Contatto:
- Anne W. Beaven
- Email: beaven@med.unc.edu
-
Danville, Illinois, Stati Uniti, 61832
- Reclutamento
- Carle at The Riverfront
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@Carle.com
-
Decatur, Illinois, Stati Uniti, 62526
- Reclutamento
- Cancer Care Specialists of Illinois - Decatur
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Stati Uniti, 62526
- Reclutamento
- Decatur Memorial Hospital
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Dixon, Illinois, Stati Uniti, 61021
- Reclutamento
- Illinois CancerCare-Dixon
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 815-285-7800
-
Effingham, Illinois, Stati Uniti, 62401
- Reclutamento
- Carle Physician Group-Effingham
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Effingham, Illinois, Stati Uniti, 62401
- Reclutamento
- Crossroads Cancer Center
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Eureka, Illinois, Stati Uniti, 61530
- Reclutamento
- Illinois CancerCare-Eureka
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Evanston, Illinois, Stati Uniti, 60201
- Reclutamento
- NorthShore University HealthSystem-Evanston Hospital
-
Investigatore principale:
- Amy Y. Wang
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-570-2109
-
Galesburg, Illinois, Stati Uniti, 61401
- Reclutamento
- Illinois CancerCare-Galesburg
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Glenview, Illinois, Stati Uniti, 60026
- Reclutamento
- NorthShore University HealthSystem-Glenbrook Hospital
-
Investigatore principale:
- Amy Y. Wang
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-570-2109
-
Highland Park, Illinois, Stati Uniti, 60035
- Reclutamento
- NorthShore University HealthSystem-Highland Park Hospital
-
Investigatore principale:
- Amy Y. Wang
-
Contatto:
- Site Public Contact
- Numero di telefono: 847-570-2109
-
Kewanee, Illinois, Stati Uniti, 61443
- Reclutamento
- Illinois CancerCare-Kewanee Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Macomb, Illinois, Stati Uniti, 61455
- Reclutamento
- Illinois CancerCare-Macomb
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Mattoon, Illinois, Stati Uniti, 61938
- Reclutamento
- Carle Physician Group-Mattoon/Charleston
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Mount Vernon, Illinois, Stati Uniti, 62864
- Reclutamento
- SSM Health Good Samaritan
-
Investigatore principale:
- Jay W. Carlson
-
Contatto:
- Site Public Contact
- Numero di telefono: 618-899-1894
- Email: gayla.hall@ssmhealth.com
-
O'Fallon, Illinois, Stati Uniti, 62269
- Reclutamento
- Cancer Care Center of O'Fallon
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Ottawa, Illinois, Stati Uniti, 61350
- Reclutamento
- Illinois CancerCare-Ottawa Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Pekin, Illinois, Stati Uniti, 61554
- Reclutamento
- Illinois CancerCare-Pekin
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Peoria, Illinois, Stati Uniti, 61615
- Reclutamento
- Illinois CancerCare-Peoria
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Peru, Illinois, Stati Uniti, 61354
- Reclutamento
- Illinois CancerCare-Peru
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Princeton, Illinois, Stati Uniti, 61356
- Reclutamento
- Illinois CancerCare-Princeton
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
Shiloh, Illinois, Stati Uniti, 62269
- Reclutamento
- Memorial Hospital East
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-747-9912
- Email: dschwab@wustl.edu
-
Investigatore principale:
- Brad S. Kahl
-
Springfield, Illinois, Stati Uniti, 62702
- Reclutamento
- Southern Illinois University School of Medicine
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-545-7929
-
Springfield, Illinois, Stati Uniti, 62702
- Reclutamento
- Springfield Clinic
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-444-7541
-
Springfield, Illinois, Stati Uniti, 62781
- Reclutamento
- Springfield Memorial Hospital
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 217-528-7541
- Email: pallante.beth@mhsil.com
-
Urbana, Illinois, Stati Uniti, 61801
- Reclutamento
- Carle Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-446-5532
- Email: Research@carle.com
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Washington, Illinois, Stati Uniti, 61571
- Reclutamento
- Illinois CancerCare - Washington
-
Contatto:
- Site Public Contact
- Numero di telefono: 309-243-3605
- Email: andersonj@illinoiscancercare.com
-
Investigatore principale:
- Bryan A. Faller
-
-
Indiana
-
Crown Point, Indiana, Stati Uniti, 46307
- Reclutamento
- Northwest Cancer Center - Crown Point
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 219-836-6879
- Email: CancerResearch@powershealth.org
-
Dyer, Indiana, Stati Uniti, 46311
- Reclutamento
- Northwest Oncology LLC
-
Contatto:
- Site Public Contact
- Numero di telefono: 219-924-8178
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Hobart, Indiana, Stati Uniti, 46342
- Reclutamento
- Northwest Cancer Center - Hobart
-
Contatto:
- Site Public Contact
- Numero di telefono: 219-947-1795
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Hobart, Indiana, Stati Uniti, 46342
- Reclutamento
- Saint Mary Medical Center
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 219-836-6875
- Email: CancerResearch@COMHS.org
-
Indianapolis, Indiana, Stati Uniti, 46312
- Reclutamento
- Saint Catherine Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 773-702-9171
- Email: protocols@AllianceNCTN.org
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Munster, Indiana, Stati Uniti, 46321
- Reclutamento
- The Community Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 219-836-3349
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Munster, Indiana, Stati Uniti, 46321
- Reclutamento
- Women's Diagnostic Center - Munster
-
Contatto:
- Site Public Contact
- Numero di telefono: 219-934-8869
- Email: mnicholson@comhs.org
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Valparaiso, Indiana, Stati Uniti, 46383
- Reclutamento
- Northwest Cancer Center - Valparaiso
-
Investigatore principale:
- Maria T. Grosse-Perdekamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 219-836-6875
- Email: CancerResearch@COMHS.org
-
-
Iowa
-
Ames, Iowa, Stati Uniti, 50010
- Reclutamento
- Mary Greeley Medical Center
-
Investigatore principale:
- Joseph J. Merchant
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-956-4132
-
Ames, Iowa, Stati Uniti, 50010
- Reclutamento
- McFarland Clinic - Ames
-
Investigatore principale:
- Joseph J. Merchant
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-239-4734
- Email: ksoder@mcfarlandclinic.com
-
Ankeny, Iowa, Stati Uniti, 50023
- Reclutamento
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
Boone, Iowa, Stati Uniti, 50036
- Sospeso
- McFarland Clinic - Boone
-
Carroll, Iowa, Stati Uniti, 51401
- Reclutamento
- Saint Anthony Regional Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-689-7658
- Email: sbenson@iora.org
-
Investigatore principale:
- Seema Harichand-Herdt
-
Clive, Iowa, Stati Uniti, 50325
- Reclutamento
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Stati Uniti, 50314
- Reclutamento
- Broadlawns Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-282-2200
-
Investigatore principale:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Stati Uniti, 50314
- Reclutamento
- Mercy Medical Center - Des Moines
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Richard L. Deming
-
Des Moines, Iowa, Stati Uniti, 50309
- Reclutamento
- Iowa Methodist Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-6727
-
Investigatore principale:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Stati Uniti, 50309
- Reclutamento
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Stati Uniti, 50314
- Reclutamento
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
Fort Dodge, Iowa, Stati Uniti, 50501
- Reclutamento
- McFarland Clinic - Trinity Cancer Center
-
Investigatore principale:
- Joseph J. Merchant
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-956-4132
-
Fort Dodge, Iowa, Stati Uniti, 50501
- Reclutamento
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Investigatore principale:
- Seema Harichand-Herdt
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-282-2921
- Email: trials@missioncancer.com
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa/Holden Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-237-1225
-
Investigatore principale:
- Eric Mou
-
Jefferson, Iowa, Stati Uniti, 50129
- Sospeso
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Stati Uniti, 50158
- Reclutamento
- McFarland Clinic - Marshalltown
-
Investigatore principale:
- Joseph J. Merchant
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-956-4132
-
Waukee, Iowa, Stati Uniti, 50263
- Reclutamento
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 515-241-3305
-
Investigatore principale:
- Seema Harichand-Herdt
-
-
Kansas
-
Hays, Kansas, Stati Uniti, 67601
- Reclutamento
- HaysMed
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 785-623-5774
-
Kansas City, Kansas, Stati Uniti, 66160
- Reclutamento
- University of Kansas Cancer Center
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Lawrence, Kansas, Stati Uniti, 66044
- Reclutamento
- Lawrence Memorial Hospital
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 785-505-2800
- Email: Stephanie.Norris@LMH.ORG
-
Leavenworth, Kansas, Stati Uniti, 66048
- Sospeso
- Veteran Administration Eastern Kansas Healthcare
-
Olathe, Kansas, Stati Uniti, 66061
- Reclutamento
- The University of Kansas Cancer Center - Olathe
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-1569
- Email: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, Stati Uniti, 66210
- Reclutamento
- University of Kansas Cancer Center-Overland Park
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Pittsburg, Kansas, Stati Uniti, 66762
- Reclutamento
- Freeman Physician Group of Pittsburg
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Email: BNMathew@freemanhealth.com
-
Salina, Kansas, Stati Uniti, 67401
- Reclutamento
- Salina Regional Health Center
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 785-452-7038
- Email: mleepers@srhc.com
-
Topeka, Kansas, Stati Uniti, 66606
- Reclutamento
- University of Kansas Health System Saint Francis Campus
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 785-295-8000
-
Westwood, Kansas, Stati Uniti, 66205
- Reclutamento
- University of Kansas Hospital-Westwood Cancer Center
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40202
- Reclutamento
- The James Graham Brown Cancer Center at University of Louisville
-
Contatto:
- Site Public Contact
- Numero di telefono: 502-562-3429
-
Investigatore principale:
- Hassaan Yasin
-
Louisville, Kentucky, Stati Uniti, 40245
- Reclutamento
- UofL Health Medical Center Northeast
-
Contatto:
- Site Public Contact
- Numero di telefono: 502-852-2755
- Email: ctoinfo@louisville.edu
-
Investigatore principale:
- Hassaan Yasin
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106
- Reclutamento
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Bay City, Michigan, Stati Uniti, 48706
- Reclutamento
- McLaren Cancer Institute-Bay City
-
Investigatore principale:
- Dipenkumar Modi
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-576-9790
- Email: ctoadmin@karmanos.org
-
Brighton, Michigan, Stati Uniti, 48114
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Brighton, Michigan, Stati Uniti, 48114
- Reclutamento
- Trinity Health Medical Center - Brighton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Canton, Michigan, Stati Uniti, 48188
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Canton, Michigan, Stati Uniti, 48188
- Reclutamento
- Trinity Health Medical Center - Canton
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Chelsea, Michigan, Stati Uniti, 48118
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Chelsea, Michigan, Stati Uniti, 48118
- Reclutamento
- Chelsea Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Clarkston, Michigan, Stati Uniti, 48346
- Reclutamento
- McLaren Cancer Institute-Clarkston
-
Investigatore principale:
- Dipenkumar Modi
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-576-9790
- Email: ctoadmin@karmanos.org
-
Detroit, Michigan, Stati Uniti, 48201
- Reclutamento
- Wayne State University/Karmanos Cancer Institute
-
Investigatore principale:
- Dipenkumar Modi
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-527-6266
- Email: ctoadmin@karmanos.org
-
Farmington Hills, Michigan, Stati Uniti, 48334
- Reclutamento
- Weisberg Cancer Treatment Center
-
Investigatore principale:
- Dipenkumar Modi
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-576-9790
- Email: ctoadmin@karmanos.org
-
Farmington Hills, Michigan, Stati Uniti, 48336
- Reclutamento
- Corewell Health Farmington Hills Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 248-551-7695
-
Investigatore principale:
- Andrew A. Muskovitz
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Genesys Hurley Cancer Institute
-
Investigatore principale:
- Christopher M. Reynolds
-
Contatto:
- Site Public Contact
- Numero di telefono: 810-762-8038
- Email: wstrong@ghci.org
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Hurley Medical Center
-
Investigatore principale:
- Christopher M. Reynolds
-
Contatto:
- Site Public Contact
- Numero di telefono: 810-762-8038
- Email: wstrong@ghci.org
-
Flint, Michigan, Stati Uniti, 48532
- Reclutamento
- McLaren Cancer Institute-Flint
-
Investigatore principale:
- Dipenkumar Modi
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-576-9790
- Email: ctoadmin@karmanos.org
-
Flint, Michigan, Stati Uniti, 48503
- Sospeso
- Genesee Hematology Oncology PC
-
Flint, Michigan, Stati Uniti, 48503
- Reclutamento
- Cancer Hematology Centers - Flint
-
Investigatore principale:
- Christopher M. Reynolds
-
Contatto:
- Site Public Contact
- Numero di telefono: 810-762-8038
- Email: wstrong@ghci.org
-
Lansing, Michigan, Stati Uniti, 48912
- Reclutamento
- University of Michigan Health - Sparrow Lansing
-
Investigatore principale:
- Christopher M. Reynolds
-
Contatto:
- Site Public Contact
- Numero di telefono: 517-364-3712
- Email: harsha.trivedi@umhsparrow.org
-
Lapeer, Michigan, Stati Uniti, 48446
- Reclutamento
- McLaren Cancer Institute-Lapeer Region
-
Investigatore principale:
- Dipenkumar Modi
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-576-9790
- Email: ctoadmin@karmanos.org
-
Livonia, Michigan, Stati Uniti, 48154
- Reclutamento
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Macomb, Michigan, Stati Uniti, 48044
- Reclutamento
- Henry Ford Saint John Hospital - Macomb Medical
-
Investigatore principale:
- Christopher M. Reynolds
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-343-3166
- Email: kforman1@hfhs.org
-
Mount Pleasant, Michigan, Stati Uniti, 48858
- Reclutamento
- McLaren Cancer Institute-Central Michigan
-
Investigatore principale:
- Dipenkumar Modi
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-576-9790
- Email: ctoadmin@karmanos.org
-
Petoskey, Michigan, Stati Uniti, 49770
- Reclutamento
- McLaren Cancer Institute-Northern Michigan
-
Investigatore principale:
- Dipenkumar Modi
-
Contatto:
- Site Public Contact
- Numero di telefono: 313-576-9790
- Email: ctoadmin@karmanos.org
-
Pontiac, Michigan, Stati Uniti, 48341
- Reclutamento
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Royal Oak, Michigan, Stati Uniti, 48073
- Reclutamento
- Corewell Health William Beaumont University Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 248-551-7695
-
Investigatore principale:
- Andrew A. Muskovitz
-
Saginaw, Michigan, Stati Uniti, 48604
- Sospeso
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Stati Uniti, 48601
- Reclutamento
- MyMichigan Medical Center Saginaw
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Tawas City, Michigan, Stati Uniti, 48764
- Reclutamento
- MyMichigan Medical Center Tawas
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Troy, Michigan, Stati Uniti, 48085
- Reclutamento
- Corewell Health Beaumont Troy Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 248-551-7695
-
Investigatore principale:
- Andrew A. Muskovitz
-
West Branch, Michigan, Stati Uniti, 48661
- Sospeso
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Stati Uniti, 48106
- Reclutamento
- Huron Gastroenterology PC
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Ypsilanti, Michigan, Stati Uniti, 48197
- Reclutamento
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contatto:
- Site Public Contact
- Numero di telefono: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Investigatore principale:
- Christopher M. Reynolds
-
-
Minnesota
-
Bemidji, Minnesota, Stati Uniti, 56601
- Reclutamento
- Sanford Joe Lueken Cancer Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-333-5000
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Brainerd, Minnesota, Stati Uniti, 56401
- Reclutamento
- Essentia Health Saint Joseph's Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Coon Rapids, Minnesota, Stati Uniti, 55433
- Reclutamento
- Mercy Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Deer River, Minnesota, Stati Uniti, 56636
- Reclutamento
- Essentia Health - Deer River Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Duluth, Minnesota, Stati Uniti, 55805
- Reclutamento
- Essentia Health Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Edina, Minnesota, Stati Uniti, 55435
- Reclutamento
- Minnesota Oncology - Edina
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Hibbing, Minnesota, Stati Uniti, 55746
- Reclutamento
- Essentia Health Hibbing Clinic
-
Investigatore principale:
- Bret E. Friday
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
-
Maplewood, Minnesota, Stati Uniti, 55109
- Reclutamento
- Saint John's Hospital - Healtheast
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Reclutamento
- Abbott-Northwestern Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Minneapolis, Minnesota, Stati Uniti, 55415
- Reclutamento
- Hennepin County Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Saint Cloud, Minnesota, Stati Uniti, 56303
- Reclutamento
- Coborn Cancer Center at Saint Cloud Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-229-4907
- Email: coborncancercenter@centracare.com
-
Investigatore principale:
- Donald J. Jurgens
-
Saint Louis Park, Minnesota, Stati Uniti, 55416
- Reclutamento
- Park Nicollet Clinic - Saint Louis Park
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Saint Paul, Minnesota, Stati Uniti, 55101
- Reclutamento
- Regions Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Saint Paul, Minnesota, Stati Uniti, 55102
- Reclutamento
- United Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
Sandstone, Minnesota, Stati Uniti, 55072
- Reclutamento
- Essentia Health Sandstone
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Virginia, Minnesota, Stati Uniti, 55792
- Reclutamento
- Essentia Health Virginia Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Woodbury, Minnesota, Stati Uniti, 55125
- Reclutamento
- Minnesota Oncology Hematology PA-Woodbury
-
Contatto:
- Site Public Contact
- Numero di telefono: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Investigatore principale:
- Yan Ji
-
-
Missouri
-
Cape Girardeau, Missouri, Stati Uniti, 63703
- Reclutamento
- Saint Francis Medical Center
-
Investigatore principale:
- Bryan A. Faller
-
Contatto:
- Site Public Contact
- Numero di telefono: 573-334-2230
- Email: sfmc@sfmc.net
-
Chesterfield, Missouri, Stati Uniti, 63017
- Reclutamento
- Saint Luke's Hospital
-
Investigatore principale:
- Mark J. Fesler
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-205-6936
-
City of Saint Peters, Missouri, Stati Uniti, 63376
- Reclutamento
- Siteman Cancer Center at Saint Peters Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Investigatore principale:
- Brad S. Kahl
-
Creve Coeur, Missouri, Stati Uniti, 63141
- Reclutamento
- Siteman Cancer Center at West County Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Investigatore principale:
- Brad S. Kahl
-
Kansas City, Missouri, Stati Uniti, 64154
- Reclutamento
- University of Kansas Cancer Center - North
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
Kansas City, Missouri, Stati Uniti, 64128
- Reclutamento
- Kansas City Veterans Affairs Medical Center
-
Investigatore principale:
- Suman Kambhampati
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-525-1483
-
Kansas City, Missouri, Stati Uniti, 64108
- Reclutamento
- University Health Truman Medical Center
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 816-404-4375
-
Kansas City, Missouri, Stati Uniti, 64116
- Reclutamento
- University of Kansas Cancer Center - Briarcliff
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
-
Lee's Summit, Missouri, Stati Uniti, 64064
- Reclutamento
- University of Kansas Cancer Center - Lee's Summit
-
Investigatore principale:
- Marc S. Hoffmann
-
Contatto:
- Site Public Contact
- Numero di telefono: 913-588-3671
- Email: KUCC_Navigation@kumc.edu
-
North Kansas City, Missouri, Stati Uniti, 64116
- Sospeso
- University of Kansas Cancer Center at North Kansas City Hospital
-
Springfield, Missouri, Stati Uniti, 65804
- Reclutamento
- Mercy Hospital Springfield
-
Investigatore principale:
- Jay W. Carlson
-
Contatto:
- Site Public Contact
- Numero di telefono: 417-269-4520
-
Springfield, Missouri, Stati Uniti, 65807
- Reclutamento
- CoxHealth South Hospital
-
Investigatore principale:
- Jay W. Carlson
-
Contatto:
- Site Public Contact
- Numero di telefono: 417-269-4520
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University School of Medicine
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Investigatore principale:
- Brad S. Kahl
-
St Louis, Missouri, Stati Uniti, 63128
- Reclutamento
- Mercy Hospital South
-
Investigatore principale:
- Jay W. Carlson
-
Contatto:
- Site Public Contact
- Numero di telefono: 314-525-6042
- Email: Danielle.Werle@mercy.net
-
St Louis, Missouri, Stati Uniti, 63129
- Reclutamento
- Siteman Cancer Center-South County
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Investigatore principale:
- Brad S. Kahl
-
St Louis, Missouri, Stati Uniti, 63136
- Reclutamento
- Siteman Cancer Center at Christian Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-600-3606
- Email: info@siteman.wustl.edu
-
Investigatore principale:
- Brad S. Kahl
-
-
Montana
-
Anaconda, Montana, Stati Uniti, 59711
- Reclutamento
- Community Hospital of Anaconda
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Billings, Montana, Stati Uniti, 59101
- Reclutamento
- Billings Clinic Cancer Center
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-996-2663
- Email: research@billingsclinic.org
-
Bozeman, Montana, Stati Uniti, 59715
- Reclutamento
- Bozeman Health Deaconess Hospital
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Great Falls, Montana, Stati Uniti, 59405
- Reclutamento
- Benefis Sletten Cancer Institute
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Kalispell, Montana, Stati Uniti, 59901
- Reclutamento
- Logan Health Medical Center
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Missoula, Montana, Stati Uniti, 59804
- Reclutamento
- Community Medical Center
-
Investigatore principale:
- John M. Schallenkamp
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
-
Nebraska
-
Bellevue, Nebraska, Stati Uniti, 68123
- Reclutamento
- Nebraska Medicine-Bellevue
-
Investigatore principale:
- Julie M. Vose
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Kearney, Nebraska, Stati Uniti, 68845
- Reclutamento
- Fred and Pamela Buffett Cancer Center - Kearney
-
Investigatore principale:
- Julie M. Vose
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Omaha, Nebraska, Stati Uniti, 68198
- Reclutamento
- University of Nebraska Medical Center
-
Investigatore principale:
- Julie M. Vose
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Omaha, Nebraska, Stati Uniti, 68118
- Reclutamento
- Nebraska Medicine-Village Pointe
-
Investigatore principale:
- Julie M. Vose
-
Contatto:
- Site Public Contact
- Numero di telefono: 402-559-5600
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03756
- Reclutamento
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-639-6918
- Email: cancer.research.nurse@dartmouth.edu
-
Investigatore principale:
- Charles Gaulin
-
-
New York
-
Buffalo, New York, Stati Uniti, 14263
- Reclutamento
- Roswell Park Cancer Institute
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-767-9355
- Email: askroswell@roswellpark.org
-
Investigatore principale:
- Chelsea Peterson
-
Camillus, New York, Stati Uniti, 13031
- Reclutamento
- Hematology Oncology Associates of CNY at Camillus
-
Contatto:
- Site Public Contact
- Numero di telefono: 315-472-7504
-
Investigatore principale:
- Steven M. Duffy
-
East Syracuse, New York, Stati Uniti, 13057
- Reclutamento
- Hematology Oncology Associates of Central New York-East Syracuse
-
Contatto:
- Site Public Contact
- Numero di telefono: 315-472-7504
-
Investigatore principale:
- Steven M. Duffy
-
Mineola, New York, Stati Uniti, 11501
- Reclutamento
- NYU Langone Hospital - Long Island
-
Investigatore principale:
- Peter Martin
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-263-4432
- Email: cancertrials@nyulangone.org
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Investigatore principale:
- Peter Martin
-
Contatto:
- Site Public Contact
- Email: CancerTrials@nyulangone.org
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- NYP/Weill Cornell Medical Center
-
Investigatore principale:
- Jia Ruan
-
Contatto:
- Site Public Contact
- Numero di telefono: 212-746-1848
-
Rochester, New York, Stati Uniti, 14642
- Reclutamento
- University of Rochester
-
Contatto:
- Site Public Contact
- Numero di telefono: 585-275-5830
-
Investigatore principale:
- Paul M. Barr
-
Webster, New York, Stati Uniti, 14580
- Reclutamento
- Wilmot Cancer Institute at Webster
-
Investigatore principale:
- Paul M. Barr
-
Contatto:
- Site Public Contact
- Email: WCICTOresearch@urmc.rochester.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27599
- Reclutamento
- UNC Lineberger Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-668-0683
- Email: cancerclinicaltrials@med.unc.edu
-
Investigatore principale:
- Anne W. Beaven
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke University Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-275-3853
-
Investigatore principale:
- Matthew S. McKinney
-
-
North Dakota
-
Bismarck, North Dakota, Stati Uniti, 58501
- Reclutamento
- Sanford Bismarck Medical Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Broadway Medical Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Fargo, North Dakota, Stati Uniti, 58103
- Reclutamento
- Essentia Health Cancer Center-South University Clinic
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Fargo, North Dakota, Stati Uniti, 58122
- Reclutamento
- Sanford Roger Maris Cancer Center
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 701-234-6161
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- Ohio State University Comprehensive Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-293-5066
- Email: Jamesline@osumc.edu
-
Investigatore principale:
- David A. Bond
-
-
Oklahoma
-
Lawton, Oklahoma, Stati Uniti, 73505
- Reclutamento
- Cancer Centers of Southwest Oklahoma Research
-
Contatto:
- Site Public Contact
- Numero di telefono: 877-231-4440
-
Investigatore principale:
- Taha Al-Juhaishi
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma Health Sciences Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Investigatore principale:
- Taha Al-Juhaishi
-
Tulsa, Oklahoma, Stati Uniti, 74146
- Reclutamento
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
Contatto:
- Site Public Contact
- Numero di telefono: 918-505-3200
-
Investigatore principale:
- Mark B. Jennings
-
-
Oregon
-
Newberg, Oregon, Stati Uniti, 97132
- Reclutamento
- Providence Newberg Medical Center
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
Ontario, Oregon, Stati Uniti, 97914
- Reclutamento
- Saint Alphonsus Cancer Care Center-Ontario
-
Contatto:
- Site Public Contact
- Numero di telefono: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Investigatore principale:
- Christopher M. Reynolds
-
Oregon City, Oregon, Stati Uniti, 97045
- Reclutamento
- Providence Willamette Falls Medical Center
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
Portland, Oregon, Stati Uniti, 97213
- Reclutamento
- Providence Portland Medical Center
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
Portland, Oregon, Stati Uniti, 97225
- Reclutamento
- Providence Saint Vincent Medical Center
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02903
- Reclutamento
- Rhode Island Hospital
-
Contatto:
- Site Public Contact
- Numero di telefono: 401-444-1488
-
Investigatore principale:
- Adam J. Olszewski
-
Westerly, Rhode Island, Stati Uniti, 02891
- Reclutamento
- Smilow Cancer Hospital Care Center - Westerly
-
Investigatore principale:
- Shalin Kothari
-
Contatto:
- Site Public Contact
- Numero di telefono: 203-785-5702
- Email: canceranswers@yale.edu
-
-
South Carolina
-
Boiling Springs, South Carolina, Stati Uniti, 29316
- Reclutamento
- Prisma Health Cancer Institute - Spartanburg
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Charleston, South Carolina, Stati Uniti, 29425
- Reclutamento
- Medical University of South Carolina
-
Contatto:
- Site Public Contact
- Numero di telefono: 843-792-9321
- Email: hcc-clinical-trials@musc.edu
-
Investigatore principale:
- Katherine Antel
-
Easley, South Carolina, Stati Uniti, 29640
- Reclutamento
- Prisma Health Cancer Institute - Easley
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- Prisma Health Cancer Institute - Faris
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29605
- Reclutamento
- Prisma Health Cancer Institute - Butternut
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Stati Uniti, 29615
- Reclutamento
- Prisma Health Cancer Institute - Eastside
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greer, South Carolina, Stati Uniti, 29650
- Reclutamento
- Prisma Health Cancer Institute - Greer
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Seneca, South Carolina, Stati Uniti, 29672
- Reclutamento
- Prisma Health Cancer Institute - Seneca
-
Investigatore principale:
- Suzanne R. Fanning
-
Contatto:
- Site Public Contact
- Numero di telefono: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Reclutamento
- Sanford Cancer Center Oncology Clinic
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicTrialsSF@sanfordhealth.org
-
Sioux Falls, South Dakota, Stati Uniti, 57117-5134
- Reclutamento
- Sanford USD Medical Center - Sioux Falls
-
Investigatore principale:
- Daniel Almquist
-
Contatto:
- Site Public Contact
- Numero di telefono: 605-312-3320
- Email: OncologyClinicalTrialsSF@SanfordHealth.org
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Reclutamento
- Huntsman Cancer Institute/University of Utah
-
Contatto:
- Site Public Contact
- Numero di telefono: 888-424-2100
- Email: cancerinfo@hci.utah.edu
-
Investigatore principale:
- Harsh Shah
-
-
Vermont
-
Saint Johnsbury, Vermont, Stati Uniti, 05819
- Reclutamento
- Dartmouth Cancer Center - North
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-639-6918
- Email: cancer.research.nurse@hitchcock.org
-
Investigatore principale:
- Charles Gaulin
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23235
- Reclutamento
- VCU Massey Cancer Center at Stony Point
-
Contatto:
- Site Public Contact
- Email: ctoclinops@vcu.edu
-
Investigatore principale:
- Bruce O. Hough
-
Richmond, Virginia, Stati Uniti, 23298
- Reclutamento
- VCU Massey Comprehensive Cancer Center
-
Investigatore principale:
- Bruce O. Hough
-
Contatto:
- Site Public Contact
- Numero di telefono: 804-628-6430
- Email: CTOclinops@vcu.edu
-
-
Washington
-
Edmonds, Washington, Stati Uniti, 98026
- Reclutamento
- Swedish Cancer Institute-Edmonds
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 206-215-2343
- Email: PCRC-NCORP@Swedish.org
-
Issaquah, Washington, Stati Uniti, 98029
- Reclutamento
- Swedish Cancer Institute-Issaquah
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 206-215-2343
- Email: PCRC-NCORP@Swedish.org
-
Seattle, Washington, Stati Uniti, 98122
- Reclutamento
- Swedish Medical Center-First Hill
-
Investigatore principale:
- Alison K. Conlin
-
Contatto:
- Site Public Contact
- Numero di telefono: 206-215-2343
- Email: PCRC-NCORP@Swedish.org
-
-
Wisconsin
-
Appleton, Wisconsin, Stati Uniti, 54911
- Reclutamento
- ThedaCare Regional Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-364-3604
- Email: ResearchDept@thedacare.org
-
Investigatore principale:
- Yazhini Vallatharasu
-
Appleton, Wisconsin, Stati Uniti, 54911
- Reclutamento
- ThedaCare Regional Medical Center - Appleton
-
Contatto:
- Site Public Contact
- Numero di telefono: 920-364-3605
- Email: ResearchDept@thedacare.org
-
Investigatore principale:
- Yazhini Vallatharasu
-
Ashland, Wisconsin, Stati Uniti, 54806
- Reclutamento
- Duluth Clinic Ashland
-
Contatto:
- Site Public Contact
- Numero di telefono: 218-786-3308
- Email: CancerTrials@EssentiaHealth.org
-
Investigatore principale:
- Bret E. Friday
-
Eau Claire, Wisconsin, Stati Uniti, 54701
- Reclutamento
- Marshfield Medical Center-EC Cancer Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Johnson Creek, Wisconsin, Stati Uniti, 53038
- Reclutamento
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Investigatore principale:
- Priyanka Pophali
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Reclutamento
- Gundersen Lutheran Medical Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 608-775-2385
- Email: cancerctr@gundersenhealth.org
-
Investigatore principale:
- Michael O. Ojelabi
-
Madison, Wisconsin, Stati Uniti, 53792
- Reclutamento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Investigatore principale:
- Priyanka Pophali
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, Stati Uniti, 53718
- Reclutamento
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Investigatore principale:
- Priyanka Pophali
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
Marshfield, Wisconsin, Stati Uniti, 54449
- Reclutamento
- Marshfield Medical Center-Marshfield
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Reclutamento
- Medical College of Wisconsin
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-805-3666
-
Investigatore principale:
- Mehdi Hamadani
-
Minocqua, Wisconsin, Stati Uniti, 54548
- Reclutamento
- Marshfield Medical Center - Minocqua
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Mukwonago, Wisconsin, Stati Uniti, 53149
- Reclutamento
- ProHealth D N Greenwald Center
-
Contatto:
- Site Public Contact
- Email: research.institute@phci.org
-
Investigatore principale:
- Timothy R. Wassenaar
-
New Berlin, Wisconsin, Stati Uniti, 53151
- Reclutamento
- Froedtert and MCW Moorland Reserve Health Center
-
Contatto:
- Site Public Contact
- Numero di telefono: 414-805-0505
-
Investigatore principale:
- Mehdi Hamadani
-
Oconomowoc, Wisconsin, Stati Uniti, 53066
- Reclutamento
- ProHealth Oconomowoc Memorial Hospital
-
Investigatore principale:
- Timothy R. Wassenaar
-
Contatto:
- Site Public Contact
- Numero di telefono: 262-928-7878
-
Rice Lake, Wisconsin, Stati Uniti, 54868
- Reclutamento
- Marshfield Medical Center-Rice Lake
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Stevens Point, Wisconsin, Stati Uniti, 54482
- Reclutamento
- Marshfield Medical Center-River Region at Stevens Point
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
Waukesha, Wisconsin, Stati Uniti, 53188
- Reclutamento
- UW Cancer Center at ProHealth Care
-
Investigatore principale:
- Timothy R. Wassenaar
-
Contatto:
- Site Public Contact
- Numero di telefono: 262-928-5539
- Email: Chanda.miller@phci.org
-
Weston, Wisconsin, Stati Uniti, 54476
- Reclutamento
- Marshfield Medical Center - Weston
-
Contatto:
- Site Public Contact
- Numero di telefono: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Investigatore principale:
- Seth O. Fagbemi
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
• Histologically confirmed mantle cell lymphoma with cyclin D1 (BCL1) expression by immunohistochemical stains and/or evidence of CCND1 rearrangement or t(11;14)(q13;q32) as confirmed by the enrolling center (such as by fluorescence in situ hybridization [FISH], polymerase chain reaction [PCR]/sequencing, karyotype). Patients with cyclin D1 and/or t(11;14) negative mantle cell lymphoma with an expression profile suggesting a diagnosis of mantle cell lymphoma [MCL] such as SOX11 expression are also eligible
-
Any stage allowed (stage I-IV)
- Patient must have at least one objective measurable disease parameter by PET or CT. Measurable disease in the liver is required if the liver is the only site of lymphoma OR bone marrow involvement by MCL
- Steroids for management of mantle cell lymphoma are allowed up to a dose of prednisone 100mg/day (or equivalent) for up to 7 days prior to registration
- No prior systemic treatment for mantle cell lymphoma
- No prior radiation treatment for stage I MCL
- No prior exposure to a BTK inhibitor or anti-CD20 monoclonal antibody
- No prior stem cell transplant
- Age >= 70 years OR age >= 60 to < 70 years with comorbidities precluding autologous stem cell transplantation (autoSCT) including at least one of the following: a) cardiac ejection fraction (EF) <= 45%, b) diffusing capacity for carbon monoxide <= 60% predicted; c) creatinine clearance < 70 but >= 30ml/minute (min); d) Eastern Cooperative Oncology Group (ECOG) performance status of 2, which poses an unacceptable risk of toxicity for high-dose therapy and stem cell transplantation; or e) Cumulative Illness Rating Scales (CIRS) total score > 6
- ECOG Performance Status 0-2
- Absolute neutrophil count (ANC) >= 750/mm^3 (without growth factor support within 7 days)
- Platelet count >= 75,000/mm^3 (or >= 50,000/mm^3 if thrombocytopenia is due to lymphoma) without growth factor support or transfusion within 7 days
- Creatinine clearance >= 30 mL/ min determined by either: a) Estimation using the Cockcroft-Gault equation or b) Measurement by nuclear medicine scan or 24 hour urine collection
- Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless documented Gilbert's syndrome)
- Aspartate transferase (AST) / alanine transaminase (ALT) =< 3 x ULN
- Patients should not be considered candidates for stem cell transplant or must have declined a stem cell transplant strategy
- No clinically significant cardiovascular disease including the following
-
Unstable angina within 3 months before registration
-
New York Heart Association class III or IV congestive heart failure
-
History of clinically significant arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes)
-
Known QT correction formula (QTcF) > 480 msecs based on Fredericia's formula (unless pacemaker in place)
-
History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- No active Hepatitis B or Hepatitis C infection. Patients with prior hepatitis B virus (HBV) exposure (positive HBV core antibody and/or surface antigen) are eligible if they have no detectable viral load, and are taking appropriate prophylactic antiviral therapy to prevent reactivation. Patients with history of hepatitis C virus (HCV) are eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- No history of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention
- No history of stroke or intracranial hemorrhage within 6 months prior to registration
- No disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. Patient must be able to swallow pills
- Potential trial participants should have recovered from major surgery
- No vaccination with a live vaccine within 35 days prior to registration
- No hypersensitivity to zanubrutinib or rituximab or any of the other ingredients of the study drugs
- Patients on strong CYP3A4 inhibitors must discontinue the drug for 14 days prior to registration on the study.
- Patients on strong CYP3A4 inducers must discontinue the drug 14 days prior to registration.
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Induction therapy (Zanubrutinib, rituximab)
Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial. |
Undergo blood sample collection Given IV Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Ancillary studies Undergo PET
Altri nomi:
Undergo colonoscopy Undergo observation Undergo EGD
Altri nomi:
Given PO undergo bone marrow biopsy Given IV |
|
Sperimentale: Arm A (Zanubrutinib)
Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. |
Undergo blood sample collection Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Ancillary studies Undergo PET
Altri nomi:
Undergo colonoscopy Undergo observation Undergo EGD
Altri nomi:
Given PO undergo bone marrow biopsy Given IV |
|
Comparatore attivo: ARM B (Observation)
Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. |
Undergo blood sample collection Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Ancillary studies Undergo PET
Altri nomi:
Undergo colonoscopy Undergo observation Undergo EGD
Altri nomi:
Given PO undergo bone marrow biopsy Given IV |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free survival (PFS) 1 (Arm A)
Lasso di tempo: Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years
|
Hazard ratios on the treatment effect will be estimated using a stratified cox proportional hazards model, stratified on age and mantle cell lymphoma (MCL) International Prognostic Index (IPI) score. The primary analysis for non-inferiority will be based on an intent-to-treat (ITT) analysis and will include all randomized patients in the analyses, regardless of eligibility or treatment status. Sensitivity analyses will also be done in an ancillary manner to evaluate and compare our endpoints using a modified ITT approach, and exclude from the analysis those classified as ineligible as well as those who withdraw right after randomization prior to any treatment/observation monitoring. |
Time from randomization until the earlier of first progression or death from any cause, assessed up to 10 years
|
|
Progression-free survival (PFS) 2 (Arm B)
Lasso di tempo: Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years
|
Hazard ratios on the treatment effect will be estimated using a stratified cox proportional hazards model, stratified on age and MCL IPI score. The primary analysis for non-inferiority will be based on an ITT analysis and will include all randomized patients in the analyses, regardless of eligibility or treatment status. Sensitivity analyses will also be done in an ancillary manner to evaluate and compare our endpoints using a modified ITT approach, and exclude from the analysis those classified as ineligible as well as those who withdraw right after randomization prior to any treatment/observation monitoring. |
Time from randomization until the earlier of second progression or death from any cause, assessed up to 10 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall survival (OS) (Arms A and B)
Lasso di tempo: Time from randomization until death from any cause, assessed up to 10 years
|
Kaplan-Meier methodology will be used to estimate the distributions of OS by treatment arm and log-rank test statistics will be used to compare these distributions between the two treatment arms. Cox Proportional Hazards models may be used to further evaluate covariates of interest with OS, including assessment of treatment effects when adjusting for other known risk factors in the model. |
Time from randomization until death from any cause, assessed up to 10 years
|
|
Incidence of adverse events
Lasso di tempo: Up to 10 years
|
Will be evaluated and captured using the CTCAE 5.0, where the type and severity grade of each adverse event will be collected and tabulated within each of the treatment arms. Perceived attribution to study treatment will also be captured. The analysis population for this secondary endpoint will include all patients who are registered and randomized on the study and receive at least one dose of study treatment. Adverse events will be monitored continuously throughout the course of the study as well as analyzed at the time of the final primary endpoint analysis. Summary statistics and frequency tables will be used to describe the distributions of adverse events. Rates of adverse events occurring in compared across the treatment arms with chi-squared tests Tolerability will also be evaluated, summarizing rates of dose delays or modifications, reasons patients end treatment, and time to end of active treatment. |
Up to 10 years
|
|
Overall response rate (ORR, complete + partial remission)
Lasso di tempo: up to 10 years
|
Will be assessed using Lugano criteria. ORR to induction is defined as the number of patients with complete or partial remission at the end of induction divided by the number of patients who receive at least one dose of the induction regimen. ORR to restart of zanubrutinib is only defined for Arm B, as the number of patients with complete or partial remission after restart of zanubrutinib divided by the number of patients that restart zanubrutinib after first disease progression following randomization. The frequencies and rates of tumor response categories will be summarized by treatment arm for response to induction as well as response to restart of zanubrutinib (Arm B only). ORR to induction and ORR to restart of zanubrutinib (Arm B only) with 95% exact binomial confidence intervals will be calculated by treatment arm. To compare the association of treatment arm and ORR to induction, chi-squared or Fisher's Exact test will be used, whichever is more appropriate at final analysis. |
up to 10 years
|
|
Complete response rate (CR)
Lasso di tempo: Up to 10 years
|
Will be assessed using Lugano criteria. CR to induction is defined as the number of patients with complete remission at the end of induction divided by the number of eligible patients who receive at least one dose of the induction regimen. CR to restart of zanubrutinib is only defined for Arm B, as the number of patients with complete remission after restart of zanubrutinib divided by the number of eligible patients that restart zanubrutinib after first disease progression following randomization. CR to induction and CR to restart of zanubrutinib (Arm B patients only) with 95% exact binomial confidence intervals will be calculated by treatment arm. To compare the association of treatment arm and CR to induction, chi-squared or Fisher's Exact test will be used, whichever is more appropriate at the time of the final analysis. |
Up to 10 years
|
|
Event-free survival (EFS) 1
Lasso di tempo: Time from randomization (Arms A and B) until the earlier of first progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
|
For EFS1, patients without an event will be censored at the last known clinical assessment. Any patient who goes to transplant will be censored at the last known clinical assessment prior to transplant. Kaplan-Meier methodology will be used to estimate the distribution of EFS. Cox Proportional Hazards models may be used to further evaluate covariates of interest with EFS. |
Time from randomization (Arms A and B) until the earlier of first progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
|
|
Event-free survival (EFS) 2
Lasso di tempo: Time from randomization (Arm B) until the earlier of second progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
|
For EFS2, patients without an event will be censored at the last known clinical assessment. Any patient who goes to transplant will be censored at the last known clinical assessment prior to transplant. Kaplan-Meier methodology will be used to estimate the distribution of EFS. Cox Proportional Hazards models may be used to further evaluate covariates of interest with EFS. |
Time from randomization (Arm B) until the earlier of second progression, start of an alternative MCL therapy, or death from any cause, assessed up to 10 years.
|
Collaboratori e investigatori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma
- Malattie emiche e linfatiche
- Linfoma, cellule del mantello
- Amministrazione dei servizi sanitari
- Aminoacidi, peptidi e proteine
- Proteine
- Tecniche investigative
- Tecniche e procedure diagnostiche
- Diagnosi
- Procedure chirurgiche, operative
- Procedure chirurgiche minimamente invasive
- Qualità dell'assistenza sanitaria
- Carboidrati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Tecniche diagnostiche, chirurgiche
- Endoscopia, gastrointestinale
- Tecniche diagnostiche, sistema digestivo
- Endoscopia
- Procedure chirurgiche del sistema digestivo
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Deossiglucosio
- Zuccheri di desossi
- Valutazione dei risultati, assistenza sanitaria
- Esito e valutazione del processo, assistenza sanitaria
- Anticorpi, monoclonali, derivati da murina
- Rituximab
- Fluorodesossiglucosio F18
- Zanubrutinib
- Colonscopia
- Spettroscopia di risonanza magnetica
- Aspetta vigile
- Endoscopia, sistema digestivo
Altri numeri di identificazione dello studio
- A052101
- NCI-2023-03577 (Altro identificatore: NCI Clinical Trial Reporting Program)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .